Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>ON</strong> +7.9%, <strong>VSM</strong> +4.8%, <strong>TSEM</strong> +3.7%, <strong>TEVA</strong> +3.6%, <strong>NSP</strong> +2.9%, <strong>FDC</strong> +2.4%, <strong>QSR</strong> +1.6%, <strong>WEX</strong> +0.6%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>ELOS</strong> +4.3% (in talks to be acquired by Apax Partners, according to Calcalist)</li></ul><p><br/> <strong>Select metal producer stocks trading higher</strong>:</p><ul><li><strong>VALE</strong> +4.9%, <strong>MT</strong> +4.8%, <strong>X</strong> +2.4%, <strong>CLF</strong> +2.4%, <strong>FCX</strong> +1.6%, <strong>RIO</strong> +1.6%, <strong>BBL</strong> +1.5%, <strong>BHP</strong> +1.1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>IMMU</strong> +7.8% (venBio comments on Immunomedics partnership announcement with Seattle Genetics (SGEN))</li><li><strong>PLUG</strong> +7.6% (continued strength following Firday's move)</li><li><strong>INO</strong> +7.5% (enters into a collaboration and license agreement providing ApolloBio with the exclusive right to develop and commercialize VGX-3100 within Greater China)</li><li><strong>AXON</strong> +4.6% (announces preliminary results from the planned interim analysis of the first 11 patients to complete its Phase 2 study of nelotanserin)</li><li><strong>SHLD</strong> +2% (continued strength following Friday's move higher)</li><li><strong>M</strong> +1.8% (Barron's profiles positive view on Macy's)</li><li><strong>MYL</strong> +1.6% (in sympathy with TEVA)</li><li><strong>PRGO</strong> +1.3% (in sympathy with TEVA)</li><li><strong>PSTI</strong> +0.9% (provides clinical updates; study initiation of the pivotal Phase III trial in CLI received clearance from regulatory authorities in the US, UK, and Germany)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>CMRE</strong> +4.7% (upgraded to Outperform from Market Perform at Wells Fargo)</li><li><strong>JCP</strong> +2.2% (upgraded to Equal-Weight from Underweight at Morgan Stanley)</li><li><strong>PBR</strong> +1.8% (upgraded to Overweight from Neutral at JP Morgan)</li></ul></td> </tr></table>"